Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics
GET POWR RATINGS... FREE!
ETON POWR Grades
- ETON scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.21% of US stocks.
- ETON's strongest trending metric is Momentum; it's been moving up over the last 175 days.
- ETON ranks lowest in Stability; there it ranks in the 28th percentile.
ETON Stock Summary
- ETON has a market capitalization of $102,341,389 -- more than approximately only 21.23% of US stocks.
- ETON PHARMACEUTICALS INC's stock had its IPO on November 13, 2018, making it an older stock than only 20.46% of US equities in our set.
- Over the past twelve months, ETON has reported earnings growth of 770.39%, putting it ahead of 97.77% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to ETON PHARMACEUTICALS INC, a group of peers worth examining would be EVLV, LUNG, YEXT, ADN, and BMRA.
- Visit ETON's SEC page to see the company's official filings. To visit the company's web site, go to www.etonpharma.com.
ETON Valuation Summary
- In comparison to the median Healthcare stock, ETON's EV/EBIT ratio is 269.7% lower, now standing at -11.2.
- Over the past 53 months, ETON's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ETON.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ETON | 2023-03-24 | 4.5 | 7.8 | -11.3 | -11.2 |
| ETON | 2023-03-23 | 4.5 | 7.9 | -11.4 | -11.3 |
| ETON | 2023-03-22 | 4.4 | 7.7 | -11.2 | -11.1 |
| ETON | 2023-03-21 | 4.5 | 7.9 | -11.5 | -11.4 |
| ETON | 2023-03-20 | 4.4 | 7.7 | -11.1 | -11.0 |
| ETON | 2023-03-17 | 4.3 | 7.6 | -11.0 | -10.8 |
ETON's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ETON has a Quality Grade of C, ranking ahead of 51.85% of graded US stocks.
- ETON's asset turnover comes in at 0.663 -- ranking 45th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ETON's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.663 | 0.885 | -1.378 |
| 2021-03-31 | 0.639 | 0.867 | -1.807 |
| 2020-12-31 | 0.002 | -6.333 | -4.051 |
| 2020-09-30 | 0.028 | -0.053 | -3.354 |
| 2020-06-30 | 0.037 | -0.009 | -4.187 |
| 2020-03-31 | 0.034 | 0.005 | -4.883 |
ETON Price Target
For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ETON Stock Price Chart Interactive Chart >
ETON Price/Volume Stats
| Current price | $3.98 | 52-week high | $4.50 |
| Prev. close | $4.06 | 52-week low | $1.95 |
| Day low | $3.95 | Volume | 8,900 |
| Day high | $4.05 | Avg. volume | 65,930 |
| 50-day MA | $3.72 | Dividend yield | N/A |
| 200-day MA | $2.92 | Market Cap | 101.32M |
Eton Pharmaceuticals, Inc. (ETON) Company Bio
Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
Latest ETON News From Around the Web
Below are the latest news stories about ETON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ETON as an investment opportunity.
When Will Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Breakeven?We feel now is a pretty good time to analyse Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) business as it appears the... |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call TranscriptEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good afternoon and welcome to the Eton Pharmaceuticals’ Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call out for your question. Please be advised […] |
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass EstimatesEton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial ResultsQ4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022. “The fourth qua |
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for |
ETON Price Returns
| 1-mo | 6.70% |
| 3-mo | 41.13% |
| 6-mo | 89.52% |
| 1-year | -6.35% |
| 3-year | -0.50% |
| 5-year | N/A |
| YTD | 41.13% |
| 2022 | -34.27% |
| 2021 | -47.23% |
| 2020 | 12.92% |
| 2019 | 17.65% |
| 2018 | N/A |
Continue Researching ETON
Want to do more research on Eton Pharmaceuticals Inc's stock and its price? Try the links below:Eton Pharmaceuticals Inc (ETON) Stock Price | Nasdaq
Eton Pharmaceuticals Inc (ETON) Stock Quote, History and News - Yahoo Finance
Eton Pharmaceuticals Inc (ETON) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...